Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00886691 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Everolimus
OTHER: Laboratory Biomarker Analysis
OTHER: Placebo

Sponsor

GOG Foundation

Collaborators

[object Object]